2024 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Welcome to the latest of our Eberhard F. Mammen award announcements. As noted in previous editorials ([Table 1]), Thieme, the publisher of Seminars in Thrombosis & Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly, 2024 represents 16 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as:

Table 1 Previous Editorials related to Eberhard F. Mammen award announcements

1. Favaloro EJ. Welcome to a Special Issue of Seminars in Thrombosis and Hemostasis—The Closing Issue for 2008. Semin Thromb Hemost 2008;34:693–696 2. Favaloro EJ. A Tribute to Eberhard F. Mammen, M.D. (1930–2008). Semin Thromb Hemost 2008;34:703–708 3. Favaloro EJ. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009; 35:1–2. 4. Favaloro EJ. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article. Semin Thromb Hemost 2009;35:587–590 5. Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award Winners. Semin Thromb Hemost 2010;36:469–470 6. Favaloro EJ. Winners of the 2010 Eberhard F. Mammen Award for Most Popular Article during 2008–2009. Semin Thromb Hemost 2010;36(7):685–92. 7. Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011;37(5):431–9. 8. Favaloro EJ. 2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012;38:425–32. 9. Favaloro EJ. 2013 Eberhard F. Mammen award announcements. Semin Thromb Hemost 39:567–74. 10. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: Part I - most popular articles. Semin Thromb Hemost 2014;40(4):407–12. 11. Favaloro EJ. 2014 Eberhard F. Mammen Award Announcements: Part II - Young Investigator Awards. Semin Thromb Hemost 2014;40(7):718–23. 12. Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2015;41(7):673–9. 13. Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2015;41(8):809–15. 14. Favaloro EJ. 2016 Eberhard F. Mammen Award Announcements: Part I - Most Popular Articles. Semin Thromb Hemost 2016;42(4):325–30. 15. Favaloro EJ. 2016 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2017;43(3):235–241. 16. Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2017;43(4):357–363. 17. Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2018;44(2):81–88. 18. Favaloro EJ. 2018 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2018;44(3):185–192. 19. Favaloro EJ. 2018 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2019;45(2):123–129. 20. Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2019;45(3):215–224. 21. Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2020;46(2):105–113 22. Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2020;46(4):383–392. 23. Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2021;47(3):229–237. 24. Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2021;47(5):467–476. 25. Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2022 Apr;48(3):265–273. 26. Favaloro EJ. 2022 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2022 Jul;48(5):502–513. 27. Favaloro EJ. 2023 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2023 Jul;49(5):417–426. 28. Favaloro EJ. 2022 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2023 Nov;49(8):775–782.

Fig. 1 Eberhard F. Mammen (1930–2008).

• ➢ Most Popular Article Awards: awarded to the authors of the most popular articles published in STH in the preceding 2 years as captured in the preceding year. The awards are determined by the Editor in Chief on the basis of user statistics from the publisher Thieme e-Journals. Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Free Access” articles, and another for a “General Category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “General Category” awards are granted “Free Access” status for these articles thereafter.

• ➢ Young Investigator Awards: best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. Previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the Senior Editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given the recent COVID-19 (coronavirus disease 2019) pandemic, many international congresses had become virtual or hybrid meetings, and accordingly, virtual meeting presentations can also be considered for the award.

Further details of the awards and the award winners are posted online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and previous award winner announcements are also available in print (see [Table 1]).

It is therefore with great pleasure that we would like to announce the latest winners of the 2024 Eberhard F. Mammen awards for the most popular articles from STH, as downloaded in 2023 and as published in the period of 2022 to 2023 inclusive.

Publikationsverlauf

Artikel online veröffentlicht:
08. März 2024

• References

• 1 Arachchillage DRJ, Pericleous C. Evolution of antiphospholipid syndrome. Semin Thromb Hemost 2023; 49 (03) 295-304
• 2 Zidan A, Noureldin A, Kumar SA, Elsebaie A, Othman M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic discrepancies and global implications. Semin Thromb Hemost 2023; 49 (01) 9-14
• 3 Bowyer AE, Gosselin RC. Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments. Semin Thromb Hemost 2023; 49 (06) 609-620
• 4 Luijten D, de Jong CMM, Ninaber MK, Spruit MA, Huisman MV, Klok FA. Post-pulmonary embolism syndrome and functional outcomes after acute pulmonary embolism. Semin Thromb Hemost 2023; 49 (08) 848-860
• 5 Ortega-Paz L, Talasaz AH, Sadeghipour P. et al. COVID-19-associated pulmonary embolism: review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (08) 816-832
• 6 Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022; 48 (01) 55-71
• 7 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2023; 49 (06) 621-633
• 8 Franchini M, Cappello E, Valdiserra G. et al. Investigating a signal of acquired hemophilia associated with COVID-19 vaccination: a systematic case review. Semin Thromb Hemost 2023; 49 (01) 15-26
• 9 Iba T, Wada H, Levy JH. Platelet activation and thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 55-61
• 10 Petersen RS, Fijen LM, Levi M, Cohn DM. Hereditary angioedema: the clinical picture of excessive contact activation. Semin Thromb Hemost 2022; (e-pub ahead of print) DOI: 10.1055/s-0042-1758820.
• 11 Grobbelaar LM, Kruger A, Venter C. et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost 2022; 48 (07) 858-868
• 12 Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023; 49 (05) 444-452
• 13 Rizk JG, Gupta A, Lazo Jr JG. et al. To anticoagulate or not to anticoagulate in COVID-19: lessons after 2 years. Semin Thromb Hemost 2023; 49 (01) 62-72
• 14 Hartmann J, Dias JD, Pivalizza EG, Garcia-Tsao G. Thromboelastography-guided therapy enhances patient blood management in cirrhotic patients: a meta-analysis based on randomized controlled trials. Semin Thromb Hemost 2023; 49 (02) 162-172
• 15 Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022; 48 (01) 8-14
• 16 Lippi G, Favaloro EJ. What we know (and do not know) regarding the pathogenesis of pulmonary thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 27-33
• 17 Hartmann J, Curzen N. Modified thromboelastography for peri-interventional assessment of platelet function in cardiology patients: a narrative review. Semin Thromb Hemost 2023; 49 (02) 192-200
• 18 Gosselin RC, Castellone D, Dorgalaleh A. et al. International Council for Standardization in Haematology guidance for new lot verification of coagulation reagents, calibrators, and controls. Semin Thromb Hemost 2023; (e-pub ahead of print) DOI: 10.1055/s-0043-1776405.
• 19 Abate V, Casoria A, Rendina D. et al. Spontaneous muscle hematoma in patients with COVID-19: a systematic literature review with description of an additional case series. Semin Thromb Hemost 2022; 48 (01) 100-108
• 20 Schellong S, Ageno W, Casella IB. et al. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE study. Semin Thromb Hemost 2022; 48 (04) 446-458
• 21 Buso G, Mazzolai L, Rueda-Camino JA. et al; RIETE Investigators. Pulmonary embolism in patients with COVID-19: comparison between different care settings. Semin Thromb Hemost 2023; 49 (01) 34-46
• 22 Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022; 48 (01) 19-30
• 23 Candeloro M, Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis. Semin Thromb Hemost 2023; 49 (01) 47-54
• 24 Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: time for a reality check?. Semin Thromb Hemost 2022; 48 (01) 72-92
• 25 Ziemba YC, Abdulrehman J, Hollestelle MJ. et al. Diagnostic testing for von Willebrand disease: trends and insights from North American laboratories over the last decade. Semin Thromb Hemost 2022; 48 (06) 700-710
• 26 Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022; 48 (08) 978-987
• 27 Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022; 48 (08) 904-910
• 28 Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug-drug interactions in the treatment of cancer-associated venous thromboembolism with direct oral anticoagulants. Semin Thromb Hemost 2024; 50 (03) 489-498
• 29 Moore GW. Testing for lupus anticoagulants. Semin Thromb Hemost 2022; 48 (06) 643-660
• 30 Morrow GB, Mutch NJ. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Semin Thromb Hemost 2023; 49 (03) 305-313
• 31 Warren BB, Moyer GC, Manco-Johnson MJ. Hemostasis in the pregnant woman, the placenta, the fetus, and the newborn infant. Semin Thromb Hemost 2023; 49 (04) 319-329
• 32 Levy-Mendelovich S, Cohen O, Klang E, Kenet G. 50 years of pediatric hemostasis: knowledge, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (03) 217-224
• 33 Nogami K. Clot waveform analysis for monitoring hemostasis. Semin Thromb Hemost 2023; 49 (06) 592-599
• 34 Lira AL, Kohs TCL, Moellmer SA, Shatzel JJ, McCarty OJT, Puy C. Substrates, cofactors, and cellular targets of coagulation factor XIa. Semin Thromb Hemost 2023; (e-pub ahead of print) DOI: 10.1055/s-0043-1764469.
• 35 Thachil J. Protamine-the journey from DNA to heparin neutralization to gene therapy. Semin Thromb Hemost 2022; 48 (02) 240-243
• 36 Pruthi RK, Chen D. The use of bypassing treatment strategies in hemophilia and their effect on laboratory testing. Semin Thromb Hemost 2023; 49 (06) 651-660
• 37 George JN. Thrombotic thrombocytopenic purpura: from 1972 to 2022 and beyond. Semin Thromb Hemost 2022; 48 (08) 926-936
• 38 Larsen JB, Hvas AM, Hojbjerg JA. Platelet function testing: update and future directions. Semin Thromb Hemost 2023; 49 (06) 600-608
• 39 Kearney KJ, Spronk HMH, Emsley J, Key NS, Philippou H. Plasma Kallikrein as a Forgotten Clotting Factor. Semin Thromb Hemost 2024; , in press. DOI: 10.1055/s-0043-57034.
• 40 Li W, Hobson EC, Bunch CM. et al. Resonant acoustic rheometry to measure coagulation kinetics in hemophilia a and healthy plasma: a novel viscoelastic method. Semin Thromb Hemost 2023; 49 (02) 201-208
• 41 Shamanaev A, Litvak M, Ivanov I. et al. Factor XII structure-function relationships. Semin Thromb Hemost 2023; (e-pub ahead of print) DOI: 10.1055/s-0043-1769509.
• 42 Valerio L, Baddour LM. Septic pulmonary embolism: a contemporary profile. Semin Thromb Hemost 2023; 49 (08) 840-847
• 43 Richard M, Celeny D, Neerman-Arbez M. Mutations accounting for congenital fibrinogen disorders: an update. Semin Thromb Hemost 2022; 48 (08) 889-903
• 44 Hirsh J, de Vries TAC, Eikelboom JW, Bhagirath V, Chan NC. Clinical studies with anticoagulants that have changed clinical practice. Semin Thromb Hemost 2023; 49 (03) 242-254
• 45 Casini A, Moerloose P, Neerman-Arbez M. One hundred years of congenital fibrinogen disorders. Semin Thromb Hemost 2022; 48 (08) 880-888
• 46 Andersson NG, Kenet G. Intracranial hemorrhages in neonates: incidence, risk factors, and treatment. Semin Thromb Hemost 2023; 49 (04) 409-415
• 47 Ichinose A, Osaki T, Souri M, Favaloro EJ. A review of autoimmune acquired von Willebrand factor deficiency in Japan. Semin Thromb Hemost 2022; 48 (08) 911-925
• 48 Malinowski AK, Abdul-Kadir R. Planning pregnancy and birth in women with inherited bleeding disorders. Semin Thromb Hemost 2023; 49 (04) 371-381
• 49 Marlar RA. Laboratory evaluation of antithrombin, protein C, and protein S. Semin Thromb Hemost 2023; 49 (06) 641-650
• 50 Woods AI, Paiva J, Dos Santos C, Alberto MF, Sánchez-Luceros A. From the discovery of ADAMTS13 to current understanding of its role in health and disease. Semin Thromb Hemost 2023; 49 (03) 284-294
• 51 Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost 2020; 46 (01) 89-95
• 52 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part I. Semin Thromb Hemost 2022; 48 (08) 871-874
• 53 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part II. Semin Thromb Hemost 2023; 49 (03) 212-216
• 54 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part III. Semin Thromb Hemost 2024; 50 (01) 4-7
• 55 Favaloro EJ, Pasalic L, Lippi G. Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT). Clin Chem Lab Med 2021; 60 (01) 7-17
• 56 Favaloro EJ, Pasalic L. Heparin-induced thrombotic thrombocytopenia (HITT) and vaccine-induced immune thrombotic thrombocytopenia (VITT): similar but different. Methods Mol Biol 2023; 2663: 405-415
• 57 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
• 58 Smock KJ, Gosselin RC. Laboratory diagnostics for thrombosis and hemostasis testing-part II. Semin Thromb Hemost 2023; 49 (06) 569-570
• 59 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part III. Semin Thromb Hemost 2022; 48 (01) 3-7